Table 1.
CTC/CTM and diagnoses in patients undergoing percutaneous CT-guided FNA or core biopsy.
| N. | Patient Age, Sex | FNAB | Core Biopsy | CTC | CTM | Stage | Final diagnosis |
|---|---|---|---|---|---|---|---|
| 1 | 81, M | Squamous cell ca | - | 3 | 1 | IIa | Squamous cell ca |
| 2 | 69, F | Adenocarcinoma | - | 2 | 3 | pT1aN2IIIa | Adenocarcinoma |
| 3 | 64, M | Squamous cell ca | - | 12 | Ia | Squamous cell ca | |
| 4 | 79, M | Adenocarcinoma | - | 2 | 4 | IV | Adenocarcinoma |
| 5 | 79, F | Adenocarcinoma | - | 8 | 2 | IV | Adenocarcinoma |
| 6 | 65, F | Mtx (Squamous cell ca) | - | 1 | 5 | - | Mtx (Squamous cell ca Head & Neck) |
| 7 | 69, F | Inflammatory cells | Inflammation | - | - | - | Inflammation |
| 8 | 74, F | Adenocarcinoma | - | 2 | 1 | IV | Adenocarcinoma |
| 9 | 66, M | Adenocarcinoma | Adenocarcinoma | 8 | 2 | IV | Adenocarcinoma |
| 10 | 87, M | Mtx (Urothelial ca) | - | - | - | - | Mtx (Urothelial ca) |
| 11 | 74, M | Squamous cell ca | - | 6 | 11 | IIIa | Squamous cell ca |
| 12 | 75, M | Adenocarcinoma | - | 6 | 23 | IV | Adenocarcinoma |
| 13 | 67, M | Adenocarcinoma | - | 6 | 2 | pT1bN0Ia | Adenocarcinoma |
| 14 | 83, M | Mtx (Squamous cell ca) | - | 6 | 4 | - | Mtx (Squamous cell ca Head & Neck) |
| 15 | 74, M | Inflammatory cells | Inflammation | - | - | - | Inflammation |
| 16 | 79, F | Adenocarcinoma | - | 4 | 3 | IIa | Adenocarcinoma |
| 17 | 74, M | Amarthocondroma | - | - | - | - | Amarthocondroma |
| 18 | 79, F | Adenocarcinoma | - | 9 | 4 | IIIa | Adenocarcinoma |
| 19 | 82, F | Adenocarcinoma | Insufficient material | - | 1 | IIIb | Adenocarcinoma |
| 20 | 81, M | Adenocarcinoma | - | 8 | 18 | IV | Adenocarcinoma |
| 21 | 64, F | Mtx (Squamous cell ca) | - | - | - | - | Mtx (Squamous cell ca Larynx) |
| 22 | 73, M | Insufficient material | - | - | - | - | Sarcoidosis |
| 23 | 75, M | Squamous cell ca | - | 2 | 5 | pT1aN0Ia | Squamous cell ca |
| 24 | 71, M | Adenocarcinoma | - | 5 | 9 | IV | Adenocarcinoma |
| 25 | 72, M | Adenocarcinoma | - | 8 | 2 | pT1bN0Ia | Adenocarcinoma |
| 26 | 65, M | Adenocarcinoma | - | - | 2 | pT1aN0Ia | Adenocarcinoma |
| 27 | 75, M | Squamous cell ca | - | 2 | - | IIIa | Squamous cell ca |
| 28 | 67, M | NSCLC NOS | - | - | 3 | IV | NSCLC NOS |
| 29 | 57, F | Adenocarcinoma | - | 5 | 1 | IIIa | Adenocarcinoma |
| 30 | 68, F | Adenocarcinoma | - | 4 | 3 | pT1aN0Ia | Adenocarcinoma |
| 31 | 78, M | Mtx (Intestinal Adenocarcinoma) | - | - | - | - | Mtx (Colon Adenocarcinoma) |
| 32 | 70, F | Adenocarcinoma | - | 4 | - | IV | Adenocarcinoma |
| 33 | 80, M | Insufficient material | Insufficient material | - | 2 | Ia | Adenocarcinoma* |
| 34 | 83, M | Adenocarcinoma | - | - | 1 | IV | Adenocarcinoma |
| 35 | 72, M | Adenocarcinoma | - | 5 | 10 | pT1bN0Ia | Adenocarcinoma |
| 36 | 83, F | Adenocarcinoma | - | - | 8 | IIIa | Adenocarcinoma |
| 37 | 75, M | Mtx (Intestinal Adenocarcinoma) | - | 2 | 4 | - | Mtx (Colon Adenocarcinoma) |
| 38 | 74, F | Adenocarcinoma | - | 4 | 1 | IV | Adenocarcinoma |
| 39 | 63, F | Adenocarcinoma | - | - | 1 | Ia | Adenocarcinoma |
| 40 | 73, F | Adenocarcinoma | Adenocarcinoma | 10 | 3 | IV | Adenocarcinoma |
| 41 | 49, F | Mtx (Breast ca) | - | 5 | 3 | Mtx (Breast ca) | |
| 42 | 81, M | Adenocarcinoma | - | 3 | 1 | Ia | Adenocarcinoma |
| 43 | 75, M | Inflammatory cells | Abscess | - | - | - | Abscess |
| 44 | 69, M | Adenocarcinoma | Adenocarcinoma | - | 3 | Ia | Adenocarcinoma |
| 45 | 51, M | Adenocarcinoma | - | 2 | 1 | Ia | Adenocarcinoma |
| 46 | 70, M | Squamous cell ca | - | - | - | pT2bN0IIa | Squamous cell ca |
| 47 | 71, M | Mtx (neuroendocrine ca) | - | 5 | 3 | - | Mtx (Neuroendocrine ca) |
| 48 | 84, M | Adenocarcinoma | Adenocarcinoma | - | - | IV | Adenocarcinoma |
| 49 | 74, M | Squamous cell ca | - | - | - | IV | Squamous cell ca |
| 50 | 64, M | Insufficient material | - | - | - | - | Amarthocondroma |
| 51 | 74, F | Squamous cell ca | - | - | - | IIIa | Squamous cell ca |
| 52 | 76, F | Adenocarcinoma | - | - | - | pT2aN0IIa | Adenocarcinoma |
| 53 | 85, F | Neuroendocrine malignant | Neuroendocrine malignant | - | - | IV-diffuse | Neuroendocrine malignant |
| 54 | 65, M | Adenocarcinoma | - | - | - | Ia | Adenocarcinoma |
| 55 | 83, M | Squamous cell ca | - | - | - | Ia | Squamous cell ca |
| 56 | 62, F | Adenocarcinoma | - | - | - | Ia | Adenocarcinoma |
| 57 | 68, F | Mtx (Breast ca) | - | 2 | 1 | - | Mtx (Breast ca) |
| 58 | 82, F | Adenocarcinoma | - | - | - | Ib | Adenocarcinoma |
| 59 | 76, M | Adenocarcinoma | - | - | - | Ia | Adenocarcinoma |
| 60 | 64, F | Neuroendocrine tumor | - | - | - | pT1aN0Ia | Typical carcinoid |
| 61 | 66, M | Carcinoid | Carcinoid | - | - | pT1aN0Ia | Typical carcinoid |
| 62 | 79, F | Insufficient material | Insufficient material | 5 | 2 | IV | Adenocarcinoma* |
| 63 | 75, F | Inconclusive | Inconclusive | 3 | 10 | pT2bN1IIb | Adenocarcinoma |
| 64 | 52, F | Mtx (Intestinal adenocarcinoma) | - | - | 4 | - | Mtx (Colon Adenocarcinoma) |
| 65 | 75, M | SCLC | - | 6 | 5 | - | SCLC |
| 66 | 83, M | NSCLC | Squamous cell ca | - | - | IIIa | Squamous cell ca |
| 67 | 29, M | Amarthocondroma | Amarthocondroma | - | - | - | Amarthocondroma |
| 68 | 72, F | Adenocarcinoma | - | - | - | Ia | Adenocarcinoma |
| 69 | 67, M | Mtx (Pancreatic Adenocarcinoma) | - | 2 | 1 | IV | Mtx (Pancreas Adenocarcinoma) |
| 70 | 55, F | Adenocarcinoma | Adenocarcinoma | - | 5 | Ib | Adenocarcinoma |
| 71 | 85, F | Squamous cell ca | Squamous cell ca | - | - | Ib | Squamous cell ca |
| 72 | 68, F | Inflammatory cells | Inflammation | - | - | - | Inflammation |
| 73 | 79, M | Mtx (intestinal Adenocarcinoma) | Mtx (intestinal Adenocarcinoma) | - | 3 | - | Mtx (Colon adenocarcinoma) |
| 74 | 75, M | Adenocarcinoma | - | - | 10 | Ib | Adenocarcinoma |
| 75 | 51, M | Squamous cell ca | Squamous cell ca | - | - | IIa | Squamous cell ca |
Ca = carcinoma; FNAB = Fine Needle Aspiration Biopsy; Mtx = metastasis; NSCLC NOS = Non Small Cell Lung Cancer Not Otherwise Specified; SCLC = Small Cell Lung Carcinoma. * Diagnosis made with Trans-Bronchial Needle Aspiration biopsy.